Patents by Inventor Bruce M. Spiegelman
Bruce M. Spiegelman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7691578Abstract: The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present invention further relates to methods for identifying new compounds that have respiration uncoupling activity.Type: GrantFiled: July 7, 2005Date of Patent: April 6, 2010Assignee: Dana-Farber Cancer Institute, Inc.Inventor: Bruce M. Spiegelman
-
Patent number: 7635708Abstract: The present invention is based on the finding that activation of PPAR? plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR? agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proliferation of such cells.Type: GrantFiled: December 19, 2002Date of Patent: December 22, 2009Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Elisabetta Mueller, Pasha Sarraf, Soner Altiok, Peter Tontonoz, Samuel Singer
-
Publication number: 20090098569Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: June 20, 2007Publication date: April 16, 2009Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Guillaume Adelmant, Pere Puigserver
-
Publication number: 20090005314Abstract: The present invention provides methods for modulating mitochondrial function, modulating lesion formation in the brain, modulating neurite growth, modulating neuronal degeneration, and treating and preventing neurological diseases or disorders comprising modulating the expression or activity of PGC-1?. The present invention also provides an animal, e.g., transgenic mouse, in which the PGC-1? gene is misexpressed. Methods for identifying compounds which are capable of treating or preventing a neurological disease or disorder are also described.Type: ApplicationFiled: September 6, 2005Publication date: January 1, 2009Inventors: Jiandie Lin, Bruce M. Spiegelman
-
Publication number: 20080262093Abstract: The present invention relates to therapeutic compositions for treating or preventing obesity and obesity-related disorders in a subject. The present invention also relates to the use of PGC-1 expression levels to determine the safe dosage range for known or putative respiration uncoupling agents for use as anti-obesity therapeutics. The present invention further relates to methods for identifying new compounds that have respiration uncoupling activity.Type: ApplicationFiled: July 7, 2005Publication date: October 23, 2008Applicant: Dana-Farber Cancer Institute, Inc.Inventor: Bruce M. Spiegelman
-
Publication number: 20080261224Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: March 10, 2008Publication date: October 23, 2008Applicant: DANA-FARBER CANCER INSTITUTE, INC.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Publication number: 20080248475Abstract: The invention provides novel methods and compositions for modulating gluconeogenesis through modulation of PGC-1 activity or expression. Also provided are methods for identifying compounds that modulate gluconeogenesis through modulation of PGC-1 activity or expression, as well as methods for identifying compounds that modulate the interaction of PGC-1 with PGC-1 target molecules. Further provided are methods for treating disorders characterized by aberrant gluconeogenesis.Type: ApplicationFiled: December 21, 2007Publication date: October 9, 2008Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Clifford Hyunsuk Yoon
-
Publication number: 20080206232Abstract: The present invention provides methods for treating lipid-related diseases and disorders, e.g., hyperlipidemia, hyper-triglyceridemia, hypercholesterolemia, cardiovascular disease, obesity, and type II diabetes, and for modulating lipid biosynthesis, lipid transport, plasma triglyceride levels and/or plasma cholesterol levels, by modulating the expression or activity of PGC-1?. Methods for identifying compounds which are capable of treating or preventing a lipid-related disease or disorder are also described.Type: ApplicationFiled: October 21, 2005Publication date: August 28, 2008Applicant: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin, Christopher B. Newgard
-
Patent number: 7371529Abstract: The invention provides novel methods and compositions for modulating gluconeogenesis through modulation of PGC-1 activity or expression. Also provided are methods for identifying compounds that modulate gluconeogenesis through modulation of PGC-1 activity or expression, as well as methods for identifying compounds that modulate the interaction of PGC-1 with PGC-1 target molecules. Further provided are methods for treating disorders characterized by aberrant gluconeogenesis.Type: GrantFiled: January 6, 2005Date of Patent: May 13, 2008Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Clifford Hyunsuk Yoon
-
Patent number: 7354738Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: April 27, 2006Date of Patent: April 8, 2008Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Patent number: 7250283Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: GrantFiled: July 3, 2002Date of Patent: July 31, 2007Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Guillaume Adelmant, Pere Puigserver
-
Patent number: 7091006Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1? nucleic acid molecules, which encode novel PGC-1 related coactivator molecules. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1? nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1? gene has been introduced or disrupted. The invention still further provides isolated PGC-1? proteins, fusion proteins, antigenic peptides and anti-PGC-1? antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: November 8, 2002Date of Patent: August 15, 2006Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Jiandie Lin
-
Patent number: 6974671Abstract: In accordance with the present invention, it has been discovered that CREB regulates hepatic gluconeogenesis via the co-activator, PGC-1. PGC-1 potentiated glucocorticoid induction of the gene for PEPCK, the rate limiting enzyme in gluconeogenesis, via the glucocorticoid response unit in the promoter, indicating that activation of PGC-1 by CREB in liver contributes to the pathogenesis of diabetes mellitus. In accordance with the above discoveries, the present invention provides a method of identifying a compound that modulates gluconeogenesis. The invention method comprises contacting CREB and a nucleic acid comprising a PGC-1 promoter with a test compound, and determining if the test compound modulates binding between CREB and the PGC-1 promoter.Type: GrantFiled: September 11, 2002Date of Patent: December 13, 2005Assignee: Salk Institute for Biological StudiesInventors: Marc R. Montminy, Bruce M. Spiegelman, Stephan Herzig
-
Patent number: 6908987Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: May 16, 2003Date of Patent: June 21, 2005Assignee: Dana-Farber Cancer Institute, Inc.Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Patent number: 6872391Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: GrantFiled: September 27, 2002Date of Patent: March 29, 2005Assignee: Dana-Farber Cancer InstituteInventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Publication number: 20040254362Abstract: The invention provides isolated nucleic acid molecules, designated PGC-1b and PGC-1c nucleic acid molecules, which encode novel isoforms of PGC-1 family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: July 20, 2004Publication date: December 16, 2004Inventors: Bruce M Spiegelman, Guillaume Adelmant, Pere Puigserver
-
Publication number: 20040077566Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of body weight disorders, including, but not limited to, obesity, overweight, anorexia, cachexia, insulin resistance, and diabetes. The invention further provides methods for identifying a compound capable of treating a body weight disorder or modulating thermogenesis. The invention also provides a method for modulating thermogenesis, e.g., modulating thermogenesis in a subject. In addition, the invention provides a method for treating a subject having a body weight disorder characterized by aberrant DHDR-2 polypeptide activity or aberrant DHDR-2 nucleic acid expression. In another aspect, the invention provides methods for modulating thermogenesis in a subject.Type: ApplicationFiled: May 9, 2002Publication date: April 22, 2004Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth Gimeno, Bruce M. Spiegelman
-
Publication number: 20030229204Abstract: The invention provides isolated nucleic acids molecules, designated PGC-1 nucleic acid molecules, which encode proteins which can modulate various adipocyte-associated activities including, for example, thermogenesis in adipocytes, e.g., brown adipocytes, and adipogenesis. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing PGC-1 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a PGC-1 gene has been introduced or disrupted. The invention still further provides isolated PGC-1 proteins, fusion proteins, antigenic peptides and anti-PGC-1 antibodies. Diagnostic, screening, and therapeutic methods utilizing compositions of the invention are also provided.Type: ApplicationFiled: May 16, 2003Publication date: December 11, 2003Inventors: Bruce M. Spiegelman, Pere Puigserver, Zhidan Wu, Guillaume Adelmant
-
Publication number: 20030212016Abstract: The present invention relates to methods and compositions for the treatment and diagnosis of body weight disorders, including, but not limited to, obesity, overweight, anorexia, cachexia, insulin resistance, and diabetes. The invention further provides methods for identifying a compound capable of treating a body weight disorder or modulating thermogenesis. The invention also provides a method for modulating thermogenesis, e.g., modulating thermogenesis in a subject. In addition, the invention provides a method for treating a subject having a body weight disorder characterized by aberrant DHDR-2 polypeptide activity or aberrant DHDR-2 nucleic acid expression. In another aspect, the invention provides methods for modulating thermogenesis in a subject.Type: ApplicationFiled: May 13, 2002Publication date: November 13, 2003Applicant: Millennium Pharmaceuticals, Inc.Inventors: Ruth Gimeno, Bruce M. Spiegelman
-
Publication number: 20030144330Abstract: The present invention is based on the finding that activation of PPAR&ggr; plays a key role in inducing growth arrest and differentiation of certain actively proliferating cells. We show that administration of PPAR&ggr; agonists, such as thiazolidinedione ligands (TZDs), is effective both in vitro and in vivo at inhibiting the proiferation of such cells.Type: ApplicationFiled: December 19, 2002Publication date: July 31, 2003Inventors: Bruce M. Spiegelman, Elisabetta Mueller, Pasha Sarraf, Soner Altiok, Peter Tontonoz, Samuel Singer